NRXP Q1 Revenue Estimate Soars to $25.57M Ahead of May 19th Report
NRXP sits 76% above its 52-week low of $1.62.
Summary
NRX Pharmaceuticals is projecting a substantial increase in revenue for Q1'26, with an estimate of $25.57 million, alongside an anticipated EPS of $0.29. This revenue estimate marks a significant jump from the company's reported revenues in prior quarters, such as $1.00 million in Q4'25, and also exceeds previous revenue estimates. For a company that recently received a 'going concern' warning in its 2025 10-K, this projected financial performance is highly material and suggests a potentially improving outlook. This positive revenue expectation could be linked to recent operational advancements, including the FDA clearance for its NRX-101 Phase 2/3 clinical trial announced on May 7th. Investors will be keenly awaiting the actual Q1'26 earnings report on May 19th to confirm if these optimistic estimates are realized.
At the time of this announcement, NRXP was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.3M. The 52-week trading range was $1.62 to $3.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.